Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia.
Adult
Aged
Area Under Curve
Aspergillosis
/ diagnosis
Biomarkers, Tumor
/ blood
Cell-Free Nucleic Acids
/ blood
Circulating MicroRNA
/ blood
Female
Gene Expression Profiling
Hematologic Neoplasms
/ complications
Humans
Invasive Fungal Infections
/ diagnosis
Male
MicroRNAs
/ genetics
Middle Aged
Neutropenia
/ complications
ROC Curve
Real-Time Polymerase Chain Reaction
Sepsis
/ blood
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 10 2020
05 10 2020
Historique:
received:
09
12
2019
accepted:
15
09
2020
entrez:
6
10
2020
pubmed:
7
10
2020
medline:
12
1
2021
Statut:
epublish
Résumé
Fungal infections represent a worrisome complication in hematologic cancer patients and in the absence of disease specific symptoms, it is important to establish new biological indicators, which can be used during mould-active prophylaxis. Recently, miRNAs have appeared as candidate diagnostic and prognostic markers of several diseases. A pilot clinical study was performed to evaluate the diagnostic utility of 14 microRNAs which can be related to invasive fungal infections. Based on our data miR-142-3p, miR-142-5p, miR-26b-5p and miR-21-5p showed significant overexpression (p < 0.005) due to invasive aspergillosis in hemato-oncology patients with profound neutropenia. A tetramiR assay was designed to monitor peripheral blood specimens. Optimal cut-off was estimated by using the median value (fold change 1.1) of the log10 transformed gene expressions. The biomarker panel was evaluated on two independent sample cohorts implementing different antimicrobial prophylactic strategies. The receiver operating characteristic analysis with area under the curve proved to be 0.97. Three miRNAs (miR-142-5p, miR-142-3p, miR-16-5p) showed significant expression alterations in episodes with sepsis. In summary, the tetramiR assay proved to be a promising diagnostic adjunct with sufficient accuracy and sensitivity to trace invasive aspergillosis in hemato-oncology patients.
Identifiants
pubmed: 33020578
doi: 10.1038/s41598-020-73556-5
pii: 10.1038/s41598-020-73556-5
pmc: PMC7536194
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Circulating MicroRNA
0
MIRN142 microRNA, human
0
MIRN16 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16532Références
Webb, B. J. et al. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 5, ofy187 (2018).
pubmed: 30151412
pmcid: 6104777
doi: 10.1093/ofid/ofy187
Samonis, G. et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 9, 2521–2526 (2013).
doi: 10.1007/s00520-013-1816-5
Dix, D. et al. Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group. Clin. Infect. Dis. 12, 1608–1614 (2012).
doi: 10.1093/cid/cis774
Pagano, L. et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 9, 1161–1170 (2007).
doi: 10.1086/522189
Badiee, P. & Hashemizadeh, Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J. Med. Res. 2, 195–204 (2014).
Ruhnke, M. et al. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). Mycoses 11, 796–813 (2018).
doi: 10.1111/myc.12838
Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 6, 1644–1655 (1992).
doi: 10.1378/chest.101.6.1644
Salih, Z. et al. Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies. South Asian J. Cancer 4, 220–224 (2013).
Taccone, F. S. et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit. Care 19, 7 (2015).
pubmed: 25928694
pmcid: 4344741
doi: 10.1186/s13054-014-0722-7
Sun, K. S., Tsai, C. F., Chen, S. C. & Huang, W. C. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS ONE 12, e0186422 (2017).
pubmed: 29049319
pmcid: 5648178
doi: 10.1371/journal.pone.0186422
Stubljar, D. & Skvarc, M. Effective strategies for diagnosis of systemic inflammatory response syndrome (SIRS) due to bacterial infection in surgical patients. Infect. Disord. Drug Targets 1, 53–56 (2015).
doi: 10.2174/1871526515666150320161804
Di Marco, M. et al. MicroRNAs in autoimmunity and hematological malignancies. Int. J. Mol. Sci. 19, 3139 (2018).
pmcid: 6213554
doi: 10.3390/ijms19103139
Zilberberg, M. D., Nathanson, B. H., Harrington, R., Spalding, J. R. & Shorr, A. F. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin. Infect. Dis. 5, 727–735 (2018).
doi: 10.1093/cid/ciy181
Dasbach, E. J., Davies, G. M. & Teutsch, S. M. Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis. 6, 1524–1528 (2000).
doi: 10.1086/317487
Lin, S. J., Schranz, J. & Teutsch, S. M. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 3, 358–366 (2001).
doi: 10.1086/318483
Cornely, O. A. et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 1, 113–122 (2009).
doi: 10.3324/haematol.11665
Shanxin, P. et al. Endogenous cellular MicroRNAs mediate antiviral defense against influenza A virus. Mol. Ther. Nucl. Acids 10, 361–375 (2018).
doi: 10.1016/j.omtn.2017.12.016
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2, 281–297 (2004).
doi: 10.1016/S0092-8674(04)00045-5
Huang, W. MicroRNAs: biomarkers, diagnostics, and therapeutics. Methods Mol. Biol. 1617, 57–67 (2017).
pubmed: 28540676
doi: 10.1007/978-1-4939-7046-9_4
pmcid: 28540676
Dix, A. et al. Specific and novel microRNAs are regulated as response to fungal infection in human dendritic cells. Front Microbiol. 23, 8–270 (2017).
Saliminejad, K., Khorram Khorshid, H. R. & Ghaffari, S. H. Why have microRNA biomarkers not been translated from bench to clinic?. Future Oncol. 8, 801–803 (2019).
doi: 10.2217/fon-2018-0812
Xu, X., Liu, C. & Bao, J. Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma. Mol. Med. Rep. 3, 1373–1378 (2017).
doi: 10.3892/mmr.2017.6139
Caserta, S. et al. Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome (SIRS). Sci. Rep. 6, 28006 (2016).
pubmed: 27320175
pmcid: 4913253
doi: 10.1038/srep28006
Gupta, M. et al. Aspergillus fumigatus induces microRNA-132 in human monocytes and dendritic cells. Int. J. Med. Microbiol. 304, 592–596 (2014).
pubmed: 24841251
doi: 10.1016/j.ijmm.2014.04.005
pmcid: 24841251
Muhammad, S. A. et al. MicroRNA expression profiling of human respiratory epithelium affected by invasive Candida infection. PLoS ONE 10, e0136454 (2015).
pubmed: 26313489
pmcid: 4551683
doi: 10.1371/journal.pone.0136454
Wu, C. X. et al. Microrna expression profiling of macrophage line raw 264.7 infected by Candida albicans. Shock 47, 520–530 (2017).
pubmed: 27749761
doi: 10.1097/SHK.0000000000000766
pmcid: 27749761
Springer, J. et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J. Clin. Microbiol. 5, 1445–1450 (2013).
doi: 10.1128/JCM.03322-12
Ceppi, M. et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. USA 8, 2735–2740 (2009).
doi: 10.1073/pnas.0811073106
Cremer, T. J. et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS ONE 4, e8508 (2009).
pubmed: 20041145
pmcid: 2794384
doi: 10.1371/journal.pone.0008508
Dumache, R. et al. Use of miRNAs as biomarkers in sepsis. Anal. Cell Pathol. 2015, 186716 (2015).
doi: 10.1155/2015/186716
Reithmar, M. et al. Cellular and extracellular miRNAs are blood-compartment-specific diagnostic targets in sepsis. J. Cell Mol. Med. 21, 2403–2411 (2017).
doi: 10.1111/jcmm.13162
Correia, C. N. et al. Circulating microRNAs as potential biomarkers of infectious disease. Front. Immunol. 8, 118 (2017).
pubmed: 28261201
pmcid: 5311051
doi: 10.3389/fimmu.2017.00118
Juan, J. G. P. Current roles of microRNAs in infectious diseases—advancing into healthcare. Redni broj lanka 781, 1331–2820 (2016).
Drury, R. E., O’Connor, D. & Pollard, A. J. The clinical application of MicroRNAs in infectious disease. Front. Immunol. 25, 8–1182 (2017).
Lacedonia, D. et al. MicroRNA expression profile during different conditions of hypoxia. Oncotarget 9, 35114–35122 (2018).
pubmed: 30416683
pmcid: 6205556
doi: 10.18632/oncotarget.26210
Bodey, G. et al. Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis. 2, 99–109 (1992).
doi: 10.1007/BF01967060
Edmond, M. B. et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 2, 239–244 (1999).
doi: 10.1086/520192
Verweij, P. E., Chowdhary, A., Melchers, W. J. & Meis, J. F. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?. Clin. Infect. Dis. 3, 362–368 (2016).
doi: 10.1093/cid/civ885
Marr, K. A., Seidel, K., White, T. C. & Bowden, R. A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 1, 309–316 (2000).
doi: 10.1086/315193
Ullmann, A. J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 4, 263–271 (2003).
doi: 10.1185/030079903125001884
Daniel, P. R. et al. Impact of bloodstream infection on outcomes among infected surgical inpatients. Ann. Surg. 4, 549–555 (2001).
Wichmann, M. W., Inthorn, D., Andress, H. J. & Schildberg, F. W. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med. 2, 167–172 (2000).
doi: 10.1007/s001340050041
Zaoutis, T. E. et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect Dis. 9, 1232–1239 (2005).
doi: 10.1086/496922
Morgan, J. et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 6, 540–547 (2005).
doi: 10.1086/502581
Pasupneti, S., Manouvakhova, O., Nicolls, M. R. & Hsu, J. L. Aspergillus-related pulmonary diseases in lung transplantation. Med. Mycol. 1, 96–102 (2017).
doi: 10.1093/mmy/myw121
Nina, S. & David, L. P. Aspergillus Infections in transplant recipients. Clin. Microbiol. Rev. 1, 44–69 (2005).
Rhodes, A. et al. Surviving sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 3, 304–377 (2017).
doi: 10.1007/s00134-017-4683-6
Dellinger, R. P. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 1, 296–327 (2008).
doi: 10.1097/01.CCM.0000298158.12101.41
Green, R. S. et al. Critical Care Interest Group. Canadian Association of Emergency Physicians Sepsis Guidelines: the optimal management of severe sepsis in Canadian emergency departments. CJEM 5, 443–459 (2008).
doi: 10.1017/S148180350001054X
Marik, P. E. et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med. 6, 1937–1949 (2008).
doi: 10.1097/CCM.0b013e31817603ba
Pottecher, T., Calvat, S., Dupont, H., Durand-Gasselin, J. & Gerbeaux, P. Haemodynamic management of severe sepsis: recommendations of the French Intensive Care Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris France. Crit. Care 10, 4–311 (2006).
doi: 10.1186/cc4965
Reinhart, K. et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger. Med. Sci. 59, 347–370 (2010).
Xie, G. H. et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit. Care 12, R5 (2008).
pubmed: 18199317
pmcid: 2374611
doi: 10.1186/cc6766
Bos, M. M., Smeets, L. S., Dumay, I. & de Jonge, E. Bloodstream infections in patients with or without cancer in a large community hospital. Infection 5, 949–958 (2013).
doi: 10.1007/s15010-013-0468-1
Wisplinghoff, H., Seifert, H., Wenzel, R. P. & Edmond, M. B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis. 29, 1103–1110 (2003).
doi: 10.1086/374339
Raad, I. I. et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 12, 1726–1734 (2006).
doi: 10.1086/504328
Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16–34 (2011).
pubmed: 21235323
doi: 10.3109/08830185.2010.529976
pmcid: 21235323
Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 33, 12481–12486 (2006).
doi: 10.1073/pnas.0605298103
O’Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G. & Baltimore, D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA 5, 1604–1609 (2007).
doi: 10.1073/pnas.0610731104
Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 8, 5082–5089 (2007).
doi: 10.4049/jimmunol.179.8.5082
Zhou, X., Li, X. & Wu, M. miRNAs reshape immunity and inflammatory responses in bacterial infection. Signal Transduct. Target Ther. 25, 3–14 (2018).
doi: 10.1038/s41392-017-0003-4
He, Y. et al. miR-26 induces apoptosis and inhibits autophagy in non-small cell lung cancer cells by suppressing TGF-β1-JNK signaling pathway. Front Pharmacol. 9, 1509 (2019).
pubmed: 30687089
pmcid: 6333751
doi: 10.3389/fphar.2018.01509
Viscoli, C. et al. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin. Infect. Dis. 11, 1532–1537 (2001).
doi: 10.1086/320514
Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 1, 133–163 (2007).
doi: 10.1128/CMR.00029-06
Syrjälä, H. et al. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur. J. Clin. Microbiol. Infect. Dis. 10, 1211–1218 (2010).
doi: 10.1007/s10096-010-0984-1
Orasch, C. et al. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 3, 521–526 (2010).
doi: 10.1038/bmt.2009.187
Nesher, L. & Rolston, K. V. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 1, 5–13 (2014).
doi: 10.1007/s15010-013-0525-9
Ibrahim, K. Y. et al. Health care-associated infections in hematology-oncology patients with neutropenia: a method of surveillance. Am. J. Infect. Control 11, 1131–1133 (2013).
doi: 10.1016/j.ajic.2013.03.299
Viscoli, C. et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur. J. Cancer 4, 430–437 (1994).
doi: 10.1016/0959-8049(94)90412-X
Faraldi, M. et al. Normalization strategies differently affect circulating miRNA profile associated with the training status. Sci. Rep. 9, 1584 (2019).
pubmed: 30733582
pmcid: 6367481
doi: 10.1038/s41598-019-38505-x
Vickers, K. C. et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 4, 423–433 (2011).
doi: 10.1038/ncb2210
Miotto, E. et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol. Biomark. Prev. 12, 2638–2642 (2014).
doi: 10.1158/1055-9965.EPI-14-0503
Moldovan, L. et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell Mol. Med. 3, 371–390 (2014).
doi: 10.1111/jcmm.12236
Kreth, S., Hübner, M. & Hinske, L. C. MicroRNAs as clinical biomarkers and therapeutic tools in perioperative medicine. Anesth Analg. 2, 670–681 (2018).
doi: 10.1213/ANE.0000000000002444
Xiao, B. et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J. Infect. Dis. 6, 916–925 (2009).
doi: 10.1086/605443
Penack, O., Rempf, P., Graf, B., Blau, I. W. & Thiel, E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann. Oncol. 5, 984–989 (2008).
doi: 10.1093/annonc/mdm571
Pfeiffer, C. D., Fine, J. P. & Safdar, N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 15, 1417–1427 (2006).
doi: 10.1086/503427
Sarrafzadeh, S. A. et al. The accuracy of serum galactomannan assay in diagnosing invasive pulmonary aspergillosis. Iran. J. Allergy Asthma Immunol. 3, 149–155 (2010).
Kaukonen, K. M., Bailey, M., Pilcher, D., Cooper, D. J. & Bellomo, R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N. Engl. J. Med. 17, 1629–1638 (2015).
doi: 10.1056/NEJMoa1415236
Chambliss, A. B., Butler-Wu, S. M. & Dien Bard, J. Diagnosis and management of sepsis and blood stream infections. J. Appl. Lab. Med. 4, 525–526 (2019).
doi: 10.1373/jalm.2018.028472
Peters, R. P., van Agtmael, M. A., Danner, S. A., Savelkoul, P. H. & Vandenbroucke-Grauls, C. M. New developments in the diagnosis of bloodstream infections. Lancet Infect. Dis. 12, 751–760 (2004).
doi: 10.1016/S1473-3099(04)01205-8
Mancini, N. et al. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin. Microbiol. Rev. 1, 235–251 (2010).
doi: 10.1128/CMR.00043-09
Gee, H. E. et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J Cancer. 7, 1168–1177 (2011).
doi: 10.1038/sj.bjc.6606076
Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 4, 348–359 (2007).
doi: 10.1056/NEJMoa061094
Dykewicz, C. A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2, 139–144 (2001).
doi: 10.1086/321805
Goodman, J. L. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 13, 845–851 (1992).
doi: 10.1056/NEJM199203263261301
De Pauw, B. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 12, 1813–1821 (2008).
doi: 10.1086/588660
Bone, R. C. et al. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit. Care Med. 5, 389–393 (1989).
doi: 10.1097/00003246-198905000-00002
Peltier, H. J. & Latham, G. J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 5, 844–852 (2008).
doi: 10.1261/rna.939908
Paholcsek, M. et al. Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia. BMC Infect. Dis. 15, 251 (2015).
pubmed: 26126706
pmcid: 4487853
doi: 10.1186/s12879-015-0995-8
Lehrnbecher, T. et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 3, 259–265 (2010).
doi: 10.1016/j.jinf.2010.06.018